Company Analysis
Sign in

Compugen Ltd. (CGEN)

Nasdaq: CGEN · Biological Products, (No Diagnostic Substances) · Holon, IL · filing with the SEC since 2001
Full chart Alerts Compare
Grade6.8
◀ Past 6.1● Present 7.2▶ Future 6.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$72.8M+161.1%
Net income$35.3M+348.4%
Earnings per share$0.38+337.5%
Operating cash flow$31.6M-36.2%
Cash$90.6M+397.0%
Debtn/a
Shareholders’ equity$103M+87.1%
Shares, diluted93.8M+4.8%
Return on equity34.4%
The recordfrom its filings
Filings in 202658
Newest filingNov 9 · 6-K
Annual reportMar 2, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$100,000
Insider buys, 12 months$0.00
Patents granted0
Filer categoryAccelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Aug 4, 2026 · SEC EDGAR · Form UPLOAD
SEC comment letter
Open the filing on sec.gov
Jul 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jul 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jul 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jul 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jul 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton CGEN · research, not advice